A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 10 → 16 locations
    • Secondary endpoints: details revised at 1 of 4 entries
    • Eligibility criteria expanded, about 3 words
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Dementia
1,982 trials monitored
See 105 trials at risk
Alzheimer's Disease
1,255 trials monitored
See 68 trials at risk
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.
Trial Details
NCT Number NCT07787182
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Related terms Alzheimer Disease, Plaque, Amyloid
Enrollment 68 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov